The present invention is directed to the discovery that AMPK activation through Galectin 9 induces autophagy and affects other related processes in response to lyosomal damage which occurs and the use of that mechanism in the treatment of autophagy disease states and/or conditions. The use of modulators of AMPK and optionally a modulator of Galectin 9, TAK1 and/or a lysosomotropic agent for the treatment of autophagy-mediated disease states and/or conditions is described as are pharmaceutical compositions.

The present invention is directed to the discovery that AMPK activation through Galectin 9 induces autophagy and affects other related processes in response to lyosomal damage which occurs and the use of that mechanism in the treatment of autophagy disease states and/or conditions. The use of modulators of AMPK and optionally a modulator of Galectin 9, TAK1 and/or a lysosomotropic agent for the treatment of autophagy-mediated disease states and/or conditions is described as are pharmaceutical compositions.

The present technology relates to synthesis of resveratrol compositions, in particular to methods of synthesizing resveratrol salicylates such as those formed through the activation of resveratrol and salicylic acid, and cosmetic and pharmaceutical compositions comprising the same.

The present technology relates to synthesis of resveratrol compositions, in particular to methods of synthesizing resveratrol salicylates such as those formed through the activation of resveratrol and salicylic acid, and cosmetic and pharmaceutical compositions comprising the same.

A singlet oxygen scavenger includes, as an active component, hexyl diethyl amino hydroxy benzoyl benzoate, 1-(4-methoxy phenyl)-3-(4-tert-butyl phenyl)-1, 3-propanedione, terephthalylidene-3, 3′-dicamphor-10, 10′-disulfonate, 2-ethyl hexyl 4-methoxy cinnamate, or 2-ethyl hexyl 2-cyano-3, 3-diphenyl acrylate; or 2-phenyl benzimidazole-5-sulfonic acid, 4, 4′, 4″-[(1, 3, 5-triazine-2, 4, 6-triyl) tris (imino)] trisbenzoic acid tris (2-ethyl hexyl), octyl salicylate, or 3, 3, 5-trimethyl cyclohexyl salicylate; or 2-hydroxy-4-methoxy-5-(sodiooxysulfonyl) benzophenone, drometrizol trisiloxane, 2-hydroxy-4-methoxy benzophenone, or 4-methyl benzylidene camphor.

A singlet oxygen scavenger includes, as an active component, hexyl diethyl amino hydroxy benzoyl benzoate, 1-(4-methoxy phenyl)-3-(4-tert-butyl phenyl)-1, 3-propanedione, terephthalylidene-3, 3′-dicamphor-10, 10′-disulfonate, 2-ethyl hexyl 4-methoxy cinnamate, or 2-ethyl hexyl 2-cyano-3, 3-diphenyl acrylate; or 2-phenyl benzimidazole-5-sulfonic acid, 4, 4′, 4″-[(1, 3, 5-triazine-2, 4, 6-triyl) tris (imino)] trisbenzoic acid tris (2-ethyl hexyl), octyl salicylate, or 3, 3, 5-trimethyl cyclohexyl salicylate; or 2-hydroxy-4-methoxy-5-(sodiooxysulfonyl) benzophenone, drometrizol trisiloxane, 2-hydroxy-4-methoxy benzophenone, or 4-methyl benzylidene camphor.

The present invention provides a patch comprising a backing layer and an adhesive agent layer, wherein the adhesive agent layer is non-aqueous, the adhesive agent layer contains nonylic acid vanillylamide and aluminum hydroxide, a content of nonylic acid vanillylamide in the adhesive agent layer is 0.01 to 0.025% by mass based on a total mass of the adhesive agent layer, a content of aluminum hydroxide in the adhesive agent layer is 0.55 to 1.5% by mass based on the total mass of the adhesive agent layer, and a mass ratio of the content of nonylic acid vanillylamide to the content of aluminum hydroxide ((content of nonylic acid vanillylamide):(content of aluminum hydroxide)) in the adhesive agent layer is 1:27 to 1:150.

The present invention provides a patch comprising a backing layer and an adhesive agent layer, wherein the adhesive agent layer is non-aqueous, the adhesive agent layer contains nonylic acid vanillylamide and aluminum hydroxide, a content of nonylic acid vanillylamide in the adhesive agent layer is 0.01 to 0.025% by mass based on a total mass of the adhesive agent layer, a content of aluminum hydroxide in the adhesive agent layer is 0.55 to 1.5% by mass based on the total mass of the adhesive agent layer, and a mass ratio of the content of nonylic acid vanillylamide to the content of aluminum hydroxide ((content of nonylic acid vanillylamide):(content of aluminum hydroxide)) in the adhesive agent layer is 1:27 to 1:150.

This document provides methods and materials involved in treating cancer. For example, this document provides methods and materials for using one or more inhibitors of a chromosomal maintenance 1 (CRM1) polypeptide in combination with one or more salicylates to treat cancer in a mammal (e.g., a human).

This document provides methods and materials involved in treating cancer. For example, this document provides methods and materials for using one or more inhibitors of a chromosomal maintenance 1 (CRM1) polypeptide in combination with one or more salicylates to treat cancer in a mammal (e.g., a human).